Showing 1 - 14 results of 14 for search 'Daver, N', query time: 0.11s
Refine Results
-
1
-
2
New directions for emerging therapies in acute myeloid leukemia: the next chapter by Daver, N, Wei, AH, Pollyea, DA, Fathi, AT, Vyas, P, DiNardo, CD
Published 2020Journal article -
3
-
4
-
5
A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute mye... by Daver, N, Vyas, P, Chao, MP, Xing, G, Renard, C, Ramsingh, G, Sallman, DA, Wei, AH
Published 2022Conference item -
6
-
7
-
8
-
9
AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies by Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, T, Masarova, L, Takahashi, K, Tippett, G, Garcia, J, Bose, P, Jabbour, E, Ravandi, F, Daver, N, Manero, GG, Vyas, P, Kantarjian, H, Konopleva, M, DiNardo, C
Published 2022Conference item -
10
AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML)... by Daver, N, Vyas, P, Kambhampati, S, Malki, MA, Larson, R, Asch, A, Mannis, G, Chai-Ho, W, Tanaka, T, Bradley, T, Jeyakumar, D, Wang, E, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, J, Sallman, D
Published 2022Conference item -
11
MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results by Sallman, D, Malki, MA, Asch, A, Wang, E, Jurcic, J, Bradley, T, Flinn, I, Pollyea, D, Kambhampati, S, Tanaka, T, Zeidner, J, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N
Published 2022Conference item -
12
Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results by Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, SN, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N
Published 2022Conference item -
13
The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results by Sallman, D, Asch, A, Kambhampati, S, Al Malki, M, Zeidner, J, Donnellan, W, Lee, D, Vyas, P, Jeyakumar, D, Mannis, G, Tanaka, T, Chai-Ho, W, Larson, R, Whiteley, A, Marcucci, G, Komrokji, R, Garcia-Manero, G, Van Elk, J, Lin, M, Maute, R, Volkmer, J-P, Takimoto, C, Chao, M, Daver, N
Published 2021Conference item -
14
AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and... by Daver, N, Montesinos, P, Aribi, A, Martinelli, G, Altman, JK, Wang, ES, Roboz, GJ, Burke, PW, Gaidano, G, Walter, RB, Thomas, X, Jeyakumar, D, DeAngelo, DJ, Erba, HP, Todisco, E, Begna, K, Advani, A, Gastaud, L, de la Fuente, A, Curti, A, Mendez, LM, Vyas, P, Boissel, N, Vey, N, Recher, C, Longval, T, Platzbecker, U, Kapp-Schwörer, S, Schliemann, C, Konopleva, M, Torres, L, Sallman, DA, Marcucci, G, Marconi, G, Kantarjian, H, Sloss, CM, Malcolm, KE, Zweidler-McKay, PA, Sweet, K
Published 2022Journal article